title: Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: therapeutic effect of plaunotol on H. pylori infection.
abstract: BACKGROUND
  It has been suggested that gastric mucosal injury induced by Helicobacter pylori infection is mediated by interleukin-8 (IL-8).
  
  
  METHODS
  We studied the effect of plaunotol, a drug extracted from the Plau-noi tree of Thailand, and reported it to be effective in the treatment of ulcers, of IL-8 secretion induced by H. pylori and of the inhibitory adhesion activity of the bacterium to gastric epithelial cells. Moreover, the therapeutic effect of plaunotol on H. pylori infection was assessed by using the gnotobiotic murine model.
  
  
  RESULTS
  Plaunotol inhibited the growth of H. pylori (1.5 x 10(4) c.f.u./mL) at high doses (24-48 microg/mL), but not at low doses (3-6 microg/mL). Interleukin-8 secretion induced by H. pylori was inhibited by coculture with plaunotol in a dose-dependent manner. The adhesion of H. pylori to MKN45 cells was also suppressed by coculture with plaunotol in a dose-dependent manner. An in vivo study showed that plaunotol improved histological gastritis and decreased the H. pylori antibody titre.
  
  
  CONCLUSIONS
  These findings suggest that plaunotol has a therapeutic effect on gastritis induced by H. pylori.
authors.affiliation: Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan. takagia@is-icc.u-tokai.ac.jp
authors.forename: A
authors.initials: A
authors.lastname: Takagi
authors.forename: Y
authors.initials: Y
authors.lastname: Koga
authors.forename: Y
authors.initials: Y
authors.lastname: Aiba
authors.forename: A M
authors.initials: AM
authors.lastname: Kabir
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: U
authors.initials: U
authors.lastname: Ohta-Tada
authors.forename: T
authors.initials: T
authors.lastname: Osaki
authors.forename: S
authors.initials: S
authors.lastname: Kamiya
authors.forename: T
authors.initials: T
authors.lastname: Miwa
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000032:analysis; D001422:Bacterial Adhesion / Q000187:drug effects; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D005233:Fatty Alcohols / Q000008:administration & dosage / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007118:Immunoassay; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000897:Anti-Ulcer Agents; D000907:Antibodies, Bacterial; D004224:Diterpenes; D005233:Fatty Alcohols; D016209:Interleukin-8; C047686:plaunotol